3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Cyclophosphamide
118
Specimen Handling
104
pembrolizumab
103
Magnetic Resonance Spectroscopy
95
fludarabine
93
Biopsy
77
Injections
53
Nivolumab
43
Bevacizumab
41
Fluorouracil
38
venetoclax
37
Cisplatin
37
Paclitaxel
35
Cetuximab
35
Carboplatin
35
Radiotherapy
31
Oxaliplatin
30
fludarabine phosphate
29
Gemcitabine
29
Leucovorin
28
Drug Therapy
25
Ipilimumab
23
Immunotherapy, Adoptive
23
Azacitidine
23
Radiation
21
Irinotecan
21
Temozolomide
20
130-nm albumin-bound paclitaxel
20
tislelizumab
19
atezolizumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recruiting
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled